Wyss Diagnostics Accelerator (DxA)

Delivering access to diagnostics for all

Play

Our mission is to enable efficient and effective delivery of diagnostics to reduce global disease burden.

Patients are at the heart of the Wyss Diagnostics Accelerator (Wyss DxA), a collaboration that brings together innovative scientists and engineers at Harvard University’s Wyss Institute for Biologically Inspired Engineering, clinicians at Brigham and Women’s Hospital, and the combined product-to-market expertise of industry partners to transform the landscape of diagnostics and save lives.

Better disease prevention and management starts with a better diagnosis.

Known as “the gateway to healthcare,” diagnostics are a critical component in identifying the cause of a patient’s illness and determining the right course of treatment. This is even more important in public health crises, like the global COVID-19 pandemic, where providing accurate and timely answers to frontline clinicians about a patient can be the difference between life and death. Despite their importance, diagnostics comprise less than 5% of hospital spending and about 1.6% of all Medicare spending, yet their findings influence as much as 60 –70% of health care decision-making.

Through this strategy, the Wyss DxA has the potential to impact millions of people worldwide across a broad spectrum of problems, from health equity to antimicrobial resistance to autoimmune conditions.